RISHP SHOWCASE 2015 C. MAXWELL M. KELLEY Minimizing Polypharmacy: Addressing Therapeutic...
-
Upload
lawrence-walsh -
Category
Documents
-
view
220 -
download
3
description
Transcript of RISHP SHOWCASE 2015 C. MAXWELL M. KELLEY Minimizing Polypharmacy: Addressing Therapeutic...
![Page 1: RISHP SHOWCASE 2015 C. MAXWELL M. KELLEY Minimizing Polypharmacy: Addressing Therapeutic Duplications.](https://reader036.fdocuments.net/reader036/viewer/2022062523/5a4d1ad57f8b9ab059972a9e/html5/thumbnails/1.jpg)
RISHP SHOWCASE 2015C. MAXWELLM. KELLEY
Minimizing Polypharmacy: Addressing Therapeutic
Duplications
![Page 2: RISHP SHOWCASE 2015 C. MAXWELL M. KELLEY Minimizing Polypharmacy: Addressing Therapeutic Duplications.](https://reader036.fdocuments.net/reader036/viewer/2022062523/5a4d1ad57f8b9ab059972a9e/html5/thumbnails/2.jpg)
Objectives
Technician Objectives: Understand when therapeutic duplications occur in
the ordering of PRN medications. Provide an example of a therapeutic duplication. Understand how guidelines can be developed to
categorize severity of common psychiatric PRN indications for medications to avoid therapeutic duplications.
![Page 3: RISHP SHOWCASE 2015 C. MAXWELL M. KELLEY Minimizing Polypharmacy: Addressing Therapeutic Duplications.](https://reader036.fdocuments.net/reader036/viewer/2022062523/5a4d1ad57f8b9ab059972a9e/html5/thumbnails/3.jpg)
Objectives
Pharmacist Objectives: Describe the process of guideline/order set
development for PRN indications of anxiety, agitation, psychoses, nausea/vomiting and constipation in a specialized psychiatric hospital and community hospitals.
Explain how use of PRN reasons defined by a guideline/order set facilitates compliance with Joint Commission standards and regulations.
Choose the appropriate PRN reason for psychiatric symptoms utilizing the provided guideline.
![Page 4: RISHP SHOWCASE 2015 C. MAXWELL M. KELLEY Minimizing Polypharmacy: Addressing Therapeutic Duplications.](https://reader036.fdocuments.net/reader036/viewer/2022062523/5a4d1ad57f8b9ab059972a9e/html5/thumbnails/4.jpg)
Therapeutic Duplication occurs when:
More than 1 med is ordered for a single indication
The level, degree, or the severity for the indication is not specified
There is not hospital policy or guideline to guide nursing staff on when a med is to be administered
![Page 5: RISHP SHOWCASE 2015 C. MAXWELL M. KELLEY Minimizing Polypharmacy: Addressing Therapeutic Duplications.](https://reader036.fdocuments.net/reader036/viewer/2022062523/5a4d1ad57f8b9ab059972a9e/html5/thumbnails/5.jpg)
Corrective Action Steps
Clarify some definitions of specific PRN Reasons in Power Plans
Revise the default PRN Reasons for some PRN orders in Power Plans
Create Hospital Guidelines that define the Degree of Severity of some common psychiatric symptoms
![Page 6: RISHP SHOWCASE 2015 C. MAXWELL M. KELLEY Minimizing Polypharmacy: Addressing Therapeutic Duplications.](https://reader036.fdocuments.net/reader036/viewer/2022062523/5a4d1ad57f8b9ab059972a9e/html5/thumbnails/6.jpg)
Guidelines for Psychiatric PRN Reasons
Guidelines are developed to categorize some common symptoms for which PRN meds are indicated
Anxiety and Severe AnxietyAgitation and Severe AgitationPsychosis and Severe Psychosis
![Page 7: RISHP SHOWCASE 2015 C. MAXWELL M. KELLEY Minimizing Polypharmacy: Addressing Therapeutic Duplications.](https://reader036.fdocuments.net/reader036/viewer/2022062523/5a4d1ad57f8b9ab059972a9e/html5/thumbnails/7.jpg)
ANXIETY SEVERE ANXIETY
Anxious, apprehensive, movements not aggressive
Physical distress, or feelings of panic
Nausea or abdominal distress
Mild trembling or shakingFeeling tense or “wound
up”Restlessness
Physical distress leading to impairment of ADL Inability to sit still or sleep Marked trembling or shaking Fear of losing control Fear of dying Feelings of panic with somatic complaints
(sweating, shortness of breath, hyperventilation, chest pain, palpitations, tachycardia,)
Paresthesia (numbness or tingling sensations) Feeling dizzy, unsteady, light-headed or faint Physical distress leading to impairment of ADL Inability to sit still or sleep Marked trembling or shaking Fear of losing control Fear of dying Feelings of panic with somatic complaints
(sweating, shortness of breath, hyperventilation, chest pain, palpitations, tachycardia,)
PRN Guideline: Anxiety
![Page 8: RISHP SHOWCASE 2015 C. MAXWELL M. KELLEY Minimizing Polypharmacy: Addressing Therapeutic Duplications.](https://reader036.fdocuments.net/reader036/viewer/2022062523/5a4d1ad57f8b9ab059972a9e/html5/thumbnails/8.jpg)
AGITATION SEVERE AGITATION
Impulsive, impatient, low tolerance for pain or frustration
Uncooperative, resistant to care, demanding
Rocking, rubbing, moaning or other self- stimulating behavior
Restlessness, pacing, excessive movement
Rapid, loud or excessive talking
Sudden changes of mood
Violent, combative and/ or threatening violence toward people or property
Explosive and/ or unpredictable anger Self- abusiveness, physical and/or verbal
Immediate danger to self or others
PRN Guideline: Agitation
![Page 9: RISHP SHOWCASE 2015 C. MAXWELL M. KELLEY Minimizing Polypharmacy: Addressing Therapeutic Duplications.](https://reader036.fdocuments.net/reader036/viewer/2022062523/5a4d1ad57f8b9ab059972a9e/html5/thumbnails/9.jpg)
PSYCHOSIS SEVERE PSYCHOSIS
Auditory or Visual Hallucinations
Delusions Paranoid Thoughts
Auditory or Visual Hallucinations with threats of harm to self or others
Delusions with threats of harm to self or others
Paranoid Thoughts with threats of harm to self or others
PRN Guideline: Psychosis
![Page 10: RISHP SHOWCASE 2015 C. MAXWELL M. KELLEY Minimizing Polypharmacy: Addressing Therapeutic Duplications.](https://reader036.fdocuments.net/reader036/viewer/2022062523/5a4d1ad57f8b9ab059972a9e/html5/thumbnails/10.jpg)
Oral IM
Anxiety – Benzodiazepines, Antihistamines
Agitation - Antipsychotics
Severe Anxiety – Benzodiazepines, Antihistamines
Severe Agitation - Antipsychotics
Default PRN Reasons in Power Plans
![Page 11: RISHP SHOWCASE 2015 C. MAXWELL M. KELLEY Minimizing Polypharmacy: Addressing Therapeutic Duplications.](https://reader036.fdocuments.net/reader036/viewer/2022062523/5a4d1ad57f8b9ab059972a9e/html5/thumbnails/11.jpg)
PRN Guidelines: Nausea/Vomiting
Order of use defined in the PowerPlans Ondansetron: Use first for N/V Promethazine: Use for N/V refractory to ondansetron Metoclopramide: Use for N/V refractory to
ondansetron and promethazine
![Page 12: RISHP SHOWCASE 2015 C. MAXWELL M. KELLEY Minimizing Polypharmacy: Addressing Therapeutic Duplications.](https://reader036.fdocuments.net/reader036/viewer/2022062523/5a4d1ad57f8b9ab059972a9e/html5/thumbnails/12.jpg)
PRN Guidelines: Constipation
Order of use defined in the PowerPlans Colace: PRN reason for stool softening
All laxatives below given with colace Senna: Use first for constipation MOM: Use if patient still constipated 24 hours after
Senna Bisacodyl PO/PR: Use if patient still constipated 12
hours after MOM If both PO/PR ordered, use least invasive route first
Miralax: Use if patient is still constipated after 48hours from initial laxative dose
![Page 13: RISHP SHOWCASE 2015 C. MAXWELL M. KELLEY Minimizing Polypharmacy: Addressing Therapeutic Duplications.](https://reader036.fdocuments.net/reader036/viewer/2022062523/5a4d1ad57f8b9ab059972a9e/html5/thumbnails/13.jpg)
Therapeutic Duplications: Next Steps
Therapeutic Duplication Policy Define order of preference for medications by indication Set criteria for IV or PO options Allow pharmacists to clarify orders per “policy/protocol”
Pharmacist responsibility at time of verification
Continual monitoring Regular audits of duplicates and corrective steps
![Page 14: RISHP SHOWCASE 2015 C. MAXWELL M. KELLEY Minimizing Polypharmacy: Addressing Therapeutic Duplications.](https://reader036.fdocuments.net/reader036/viewer/2022062523/5a4d1ad57f8b9ab059972a9e/html5/thumbnails/14.jpg)
Summary
TJC and DOH are focused on Therapeutic Duplications
Most commonly found duplicate orders: Pain Agitation/anxiety Nausea/vomiting Constipation
Creation of PowerOrders and a policy Minimize prescribing of duplications Provide clarification when duplications exist
Goal is to minimize patient harm, adverse drug events and unclear orders